References
- Emile JF, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016;127(22):2672–2682. doi:10.1182/blood-2016-01-690636.
- Swerdlow S, Campo E, Harris N, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed.; IARC: Lyon, France, 2017.
- Bucsky P, Maarten Egeler R. Malignant histiocytic disorders in children. clinical and therapeutic approaches with a nosologic discussion. Hematol. Oncol. Clin. North Am. 1998;12(2):465–471.
- Skala SL, Lucas DR, Dewar R. Histiocytic sarcoma: review, discussion of transformation from B-cell lymphoma, and differential diagnosis. Arch Pathol Lab Med. 2018;142(11):1322–1329. doi:10.5858/arpa.2018-0220-RA.
- Feldman AL, Arber DA, Pittaluga S, et al. Clonally related follicular lymphomas and histiocytic/dendritic cell sarcomas: Evidence for transdifferentiation of the follicular lymphoma clone. Blood. 2008;111(12):5433–5439. doi:10.1182/blood-2007-11-124792.
- Wang E, Hutchinson CB, Huang Q, et al. Histiocytic sarcoma arising in indolent small B-cell lymphoma: report of two cases with molecular/genetic evidence suggestive of a “'transdifferentiation' during the clonal evolution”. Leuk Lymphoma. 2010;51(5):802–812. doi:10.3109/10428191003699845.
- Shao H, Xi L, Raffeld M, et al. Clonally related histiocytic/dendritic cell sarcoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a study of seven cases. Mod Pathol. 2011;24(11):1421–1432. doi:10.1038/modpathol.2011.102.
- Soslow RA, Davis RE, Warnke RA, Cleary ML, Kamel OW. True histiocytic lymphoma following therapy for lymphoblastic neoplasms. Blood. 1996;87(12):5207–5212.
- Kumar R, Khan SP, Joshi DD, et al. Pediatric histiocytic sarcoma clonally related to precursor B-cell acute lymphoblastic leukemia with homozygous deletion of CDKN2A encoding p16INK4A. Pediatr Blood Cancer. 2011;56(2):307–310. doi:10.1002/pbc.22810.
- Pillon M, Mussolin L, Carraro E, et al. Detection of prognostic factors in children and adolescents with Burkitt and diffuse large B-cell lymphoma treated with the AIEOP LNH-97 protocol. Br J Haematol. 2016;175(3):467–475. doi:10.1111/bjh.14240.
- Griffin TC, Weitzman S, Weinstein H, et al. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2009;52(2):177–181. doi:10.1002/pbc.21753.
- Dunleavy K, Pittaluga S, Maeda L, et al. Dose-adjusted EPOCH-Rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;368(15):1408–1416. doi:10.1056/NEJMoa1214561.
- Ornvold K, Carstensen H, Junge J, Gyhrs A, Ralfkiaer E. Tumours classified as “malignant histiocytosis” in children are T-cell neoplasms. APMIS. 1992;100(6):558–566. doi:10.1111/j.1699-0463.1992.tb00911.x.
- Shanmugam V, Griffin GK, Jacobsen ED, et al. Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma. Mod Pathol. 2019;32(6):830–843. doi:10.1038/s41379-018-0200-x.
- Castro ECC, Blazquez C, Boyd J, et al. Clinicopathologic features of histiocytic lesions following ALL, with a review of the literature. Pediatr Dev Pathol. 2010;13(3):225–237. doi:10.2350/09-03-0622-OA.1.
- Xie H, Ye M, Feng R, Graf T, York N. Stepwise reprogramming of B cells into macrophages. Cell. 2004;117(5):663–676. doi:10.1016/S0092-8674(04)00419-2.
- Cobaleda C, Jochum W, Busslinger M. Conversion of mature B cells into T cells by dedifferentiation to uncommitted progenitors. Nature. 2007;449(7161):473–477. doi:10.1038/nature06159.
- Mainardi C, D'Amore ESG, Pillon M, Toffolutti T, Rosolen A. A case of resistant pediatric histiocytic sarcoma successfully treated with chemo-radiotherapy and autologous peripheral blood stem cell transplant. Leuk Lymphoma. 2011;52(7):1367–1371. doi:10.3109/10428194.2011.565840.